...
首页> 外文期刊>Clinica chimica acta: International journal of clinical chemistry and applied molecular biology >UGT1A1 (TA)_n genotyping in sickle-cell disease: High resolution melting (HRM) curve analysis or direct sequencing, what is the best way?
【24h】

UGT1A1 (TA)_n genotyping in sickle-cell disease: High resolution melting (HRM) curve analysis or direct sequencing, what is the best way?

机译:镰状细胞病的UGT1A1(TA)_n基因分型:高分辨率熔解(HRM)曲线分析或直接测序,最佳方法是什么?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Minucci et al. have proposed in 2010 a rapid, simple and cost-effective HRM method on the LightCycler 480~R apparatus (Roche) for the determination of the 6/6, 6/7 and 7/7 genotypes of the (TA)_n UGT1A1 promoter polymorphism. However, they have not studied the n = 5 and n = 8 alleles which can be quite frequent in sickle-cell disease patients. Methods: The aim of our study was to test this HRM protocol to all the 10 possible (TA)_n UGT1A1 genotypes (i.e. 5/5, 5/6, 5/7, 5/8, 6/6, 6/7, 6/8, 7/7, 7/8 and 8/8) by using our SCD cohort of patients. Results: All genotypes could be unambiguously identified except 6/7 and 6/8 which give a similar HRM profile. For those two genotypes, the differentiation necessitates either a direct Sanger sequencing or a second PCR protocol followed by a 3% agarose gel migration.Conclusions: For the (TA)_n UGT1A1 promoter genotyping of African patients, each lab has to wonder what is the best way between (i) direct Sanger sequencing of all patients and (ii) HRM protocol for all patients followed by a complementary analysis to differentiate the 6/7 and 6/8 genotypes.
机译:背景:Minucci等。在2010年提出了一种在LightCycler 480〜R仪器(Roche)上快速,简单且经济高效的HRM方法,用于确定(TA)_n UGT1A1启动子多态性的6 / 6、6 / 7和7/7基因型。 。但是,他们尚未研究在镰状细胞病患者中可能非常常见的n = 5和n = 8等位基因。方法:我们研究的目的是针对所有10种(TA)_n UGT1A1基因型(即5 / 5、5 / 6、5 / 7、5 / 8、6 / 6、6 / 7, 6 / 8、7 / 7、7 / 8和8/8)使用我们的SCD患者队列。结果:除6/7和6/8给出相似的HRM谱外,所有基因型均可被明确鉴定。对于这两种基因型,区分需要直接进行Sanger测序或第二种PCR方案,然后进行3%琼脂糖凝胶迁移。结论:对于非洲患者的(TA)_n UGT1A1启动子基因型,每个实验室都必须知道什么是基因突变。 (i)对所有患者进行直接Sanger测序和(ii)对所有患者进行HRM方案之间的最佳方法,然后进行补充分析以区分6/7和6/8基因型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号